SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.11-2.6%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who started this subject6/14/2001 9:15:39 AM
From: nigel bates  Read Replies (1) of 52153
 
Anyone feeling a little uncomfortable about the Festo case ? PDLI's IP counsel seems to be.
It merits discussion at the very least.

Decent articles in SciAm (offline) and Herring -
redherring.com
...biotech lawyers are in such a dither about the Festo case, a recent patent-infringement decision that has fundamentally changed the balance of power that has long favored patent holders over those who deliberately or incidentally design products based on similar science. It also raises questions about the scope of some 1.2 million technology patents prosecuted in accordance with the pre-Festo system.
The case, as some see it, virtually eliminates the so-called doctrine of equivalents...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News